Published in Arterioscler Thromb Vasc Biol on April 29, 2010
Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol (2013) 1.68
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery (2010) 0.97
Novel mechanisms of abdominal aortic aneurysms. Curr Atheroscler Rep (2012) 0.95
Carboxypeptidases in disease: insights from peptidomic studies. Proteomics Clin Appl (2014) 0.83
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J Thromb Haemost (2015) 0.78
Recent Advances in the Development of Experimental Animal Models Mimicking Human Aortic Aneurysms. Vasc Specialist Int (2015) 0.75
Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA (2007) 3.44
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg (2009) 2.51
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet (2009) 2.50
SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg (2009) 2.16
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst (2008) 2.11
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Flow loading induces macrophage antioxidative gene expression in experimental aneurysms. Arterioscler Thromb Vasc Biol (2002) 1.96
Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A (2005) 1.84
Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest (2012) 1.84
MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med (2012) 1.73
Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol (2013) 1.68
Medical management of small abdominal aortic aneurysms. Circulation (2008) 1.67
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Quantification of hemodynamics in abdominal aortic aneurysms during rest and exercise using magnetic resonance imaging and computational fluid dynamics. Ann Biomed Eng (2010) 1.61
Allometric scaling of wall shear stress from mice to humans: quantification using cine phase-contrast MRI and computational fluid dynamics. Am J Physiol Heart Circ Physiol (2006) 1.57
The three-dimensional micro- and nanostructure of the aortic medial lamellar unit measured using 3D confocal and electron microscopy imaging. Matrix Biol (2007) 1.56
Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med (2010) 1.54
Circulating markers of abdominal aortic aneurysm presence and progression. Circulation (2008) 1.47
Aneurysm-related death: primary endpoint analysis for comparison of open and endovascular repair. J Vasc Surg (2002) 1.44
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem (2003) 1.43
Genomic structures of the human and murine corin genes and functional GATA elements in their promoters. J Biol Chem (2002) 1.37
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol (2009) 1.30
Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem (2003) 1.27
Influences of aortic motion and curvature on vessel expansion in murine experimental aneurysms. Arterioscler Thromb Vasc Biol (2010) 1.26
Hemodynamic regulation of CD34+ cell localization and differentiation in experimental aneurysms. Arterioscler Thromb Vasc Biol (2004) 1.26
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood (2012) 1.26
Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med (2008) 1.23
Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem (2003) 1.22
Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem (2002) 1.21
Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol (2009) 1.19
Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J Biol Chem (2004) 1.17
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol (2012) 1.12
In vivo quantification of murine aortic cyclic strain, motion, and curvature: implications for abdominal aortic aneurysm growth. J Magn Reson Imaging (2010) 1.12
Hemodynamic forces regulate mural macrophage infiltration in experimental aortic aneurysms. Exp Mol Pathol (2004) 1.11
Long-term results after accessory renal artery coverage during endovascular aortic aneurysm repair. J Vasc Surg (2012) 1.10
Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg (2010) 1.09
Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum (2009) 1.07
Postprocedural microembolic events following carotid surgery and carotid angioplasty and stenting. J Vasc Surg (2007) 1.07
Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem (2008) 1.06
Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood (2006) 1.05
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol (2008) 1.03
Rev-erbalpha upregulates NF-kappaB-responsive genes in vascular smooth muscle cells. FEBS Lett (2004) 1.03
Early experience with the snorkel technique for juxtarenal aneurysms. J Vasc Surg (2012) 1.03
Simulation-based endovascular skills assessment: the future of credentialing? J Vasc Surg (2008) 1.03
Treatment of abdominal aortic anastomotic pseudoaneurysm with percutaneous coil embolization. J Vasc Surg (2002) 1.02
Endothelial fate mapping in mice with pulmonary hypertension. Circulation (2013) 1.02
Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J Biol Chem (2008) 1.01
Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm. Physiol Genomics (2011) 1.01
Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem (2003) 1.00
Efficacy of a novel class of RNA interference therapeutic agents. PLoS One (2012) 0.99
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg (2002) 0.99
Comparison of cell-type-specific vs transmural aortic gene expression in experimental aneurysms. J Vasc Surg (2005) 0.98
Quantification of particle residence time in abdominal aortic aneurysms using magnetic resonance imaging and computational fluid dynamics. Ann Biomed Eng (2010) 0.98
Hemodynamic changes quantified in abdominal aortic aneurysms with increasing exercise intensity using mr exercise imaging and image-based computational fluid dynamics. Ann Biomed Eng (2011) 0.98
Structural requirements for the activation of human factor VIII by thrombin. Blood (2002) 0.97
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery (2010) 0.97
A survey of demographics, motivations, and backgrounds among applicants to the integrated 0 + 5 vascular surgery residency. J Vasc Surg (2010) 0.97
A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract (2009) 0.97
RGD-conjugated human ferritin nanoparticles for imaging vascular inflammation and angiogenesis in experimental carotid and aortic disease. Mol Imaging Biol (2012) 0.96
A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One (2013) 0.96
Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate. J Biol Chem (2003) 0.95
Hemodynamic influences on abdominal aortic aneurysm disease: Application of biomechanics to aneurysm pathophysiology. Vascul Pharmacol (2010) 0.95
AAA disease: mechanism, stratification, and treatment. Ann N Y Acad Sci (2006) 0.94
Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg (2004) 0.93
Wall shear stress and strain modulate experimental aneurysm cellularity. J Vasc Surg (2003) 0.93
Bioadhesive film formed from a novel organic-inorganic hybrid gel for transdermal drug delivery system. Eur J Pharm Biopharm (2011) 0.93
Cardiopulmonary exercise testing in small abdominal aortic aneurysm: profile, safety, and mortality estimates. Eur J Cardiovasc Prev Rehabil (2011) 0.93
Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem (2005) 0.91
Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem (2011) 0.91
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res (2004) 0.90
Assessment of elastase-induced murine abdominal aortic aneurysms: comparison of ultrasound imaging with in situ video microscopy. J Biomed Biotechnol (2011) 0.90
Weaving hypothesis of cardiomyocyte sarcomeres: discovery of periodic broadening and narrowing of intercalated disk during volume-load change. Am J Pathol (2010) 0.90
Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim Biophys Sin (Shanghai) (2009) 0.90
Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography. Circ Cardiovasc Imaging (2013) 0.89
Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun (2005) 0.89
Aortoiliac hemodynamic and morphologic adaptation to chronic spinal cord injury. J Vasc Surg (2006) 0.89
RORalpha1 and RORalpha4 suppress TNF-alpha-induced VCAM-1 and ICAM-1 expression in human endothelial cells. FEBS Lett (2004) 0.88